What question did this study set out to answer?

This research aims to evaluate a sensitive method for detecting peripheral residual disease (PRD) in multiple myeloma patients.

June 20, 2026HemaSphereOpen Access

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates ctDNA detection for predicting relapse in multiple myeloma, suggesting better monitoring methods.

This research aims to evaluate a sensitive method for detecting peripheral residual disease (PRD) in multiple myeloma patients.
Analyzed longitudinal samples from 84 patients enrolled in PETHEMA/GEM clinical trials.
Assessed BM-MRD using EuroFlow-based next-generation flow cytometry (NGF) and PRD using AltumTrackSeq®.
Utilized patient-specific multiplexed amplicon mini-panels targeting somatic mutations identified at diagnosis.
ctDNA-NGS showed a higher positive predictive value (PPV) of 88.9% compared to 34.5% for BM-MRD by NGF.
Specificity improved to 98.4% with ctDNA-NGS versus 70.3% with traditional methods.
Detectable ctDNA had a high risk of progression and/or death (HR 11.5; 95% CI 2.66–49.4).

Buenache et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark